

US PATENT AND TRADEMARK OFFICE INSTITUTES INTER PARTES REVIEW PROCEEDING AGAINST KEY JUBLIA® PATENT

Acrux (ASX: ACR) today announced that the U.S. Patent and Trademark Office (PTO) has instituted an *inter partes* review (IPR) proceeding filed by Acrux against U.S. Patent No. 7,214,506 owned by Kaken Pharmaceutical Co., Ltd. and licensed to Valeant Pharmaceuticals International Inc. The patent relates to methods of using various antifungal compounds, including efinaconazole, for the treatment of onychomycosis.

With the IPR now initiated, the PTO will issue a scheduling order which is expected to result in a final written decision within 12 to 18 months.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

